drugset / Trial / NCT01181986
The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes
Phase 4
Completed
76 enrolled
Carl T. Hayden VA Medical Center
American Diabetes Association · collabAmylin Pharmaceuticals, LLC. · collab
RandomizedCrossoverQuadruple-blindBasic science
Summary
The purpose of this investigation is to evaluate whether exenatide, a type 2 diabetes medication, will improve the function of the innermost part of the arterial wall called the endothelium after a fat-enriched meal and to determine how this occurs. The results of this study will help to determine and understand a novel action of this group of diabetes medications based on the action of naturally occuring gut substances called incretins. This may have a significant impact on cardiovascular health in patients with early and longstanding diabetes.
Timeline
- Start
- 2010-08
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avexitide | Peptide | 600 unknown | Intravenous |
| Subject | Exenatide | Peptide | 50 ng | Subcutaneous |
| Subject | Exenatide | Peptide | 5 ug | Subcutaneous |
| Subject | Exenatide | Peptide | 10 ug | Subcutaneous |